Unicycive Therapeutics, Inc. (UNCY)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Unicycive Therapeutics, Inc. (UNCY)

Company Performance

Current Price

as of Oct 16, 2024

$0.41

P/E Ratio

N/A

Market Cap

$38.54M

Description

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Metrics

Overview

HQLos Altos, CA
SectorHealth Technology
IndustryBiotechnology
TickerUNCY
Price$0.4084+2.10%

Trading Information

Market Cap$38.54M
Float89.59%
Average Daily Volume (1m)1,586,849
Average Daily Volume (3m)2,358,785
EPS-$0.89

Company

RevenueN/A
Rev Growth (1yr)N/A
Net Income$3.93M
Gross MarginN/A
EBITDA MarginN/A
EBITDA-$7.40M

EV$24.04M
EV/RevenueN/A
P/EN/A
P/SN/A
P/BN/A

Documents

Factset Street Account

Unicycive Therapeutics reports Q3 EPS ($0.13) vs year-ago ($0.37) ($0.52, 0.00) (2023-11-14T21:21:23Z)

Unicycive Therapeutics reaches alignment with the FDA on path to file New Drug Application for Oxylanthanum Carbonate (OLC) ($0.87, 0.00) (2023-10-23T11:06:50Z)

Unicycive Therapeutics enrolls first patient in trial for Oxylanthanum carbonate in patients with chronic kidney disease on dialysis ($0.57, 0.00) (2023-12-18T12:08:21Z)